About SimBioSys
SimBioSys is a company based in Chicago (United States) founded in 2016 by Joseph Peterson and John Cole. SimBioSys has raised $20.25 million across 2 funding rounds from investors including Mayo Clinic, Genoa Ventures and AV8 Ventures. SimBioSys offers products and services including TumorSight Viz, TumorSight RISK, and PhenoScope. SimBioSys operates in a competitive market with competitors including Qure.ai, Subtle Medical, Perspectum, Zebra Medical Vision and Invicro, among others.
- Headquarter Chicago, United States
- Founders Joseph Peterson, John Cole
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Simbiosys Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$20.25 M (USD)
in 2 rounds
-
Latest Funding Round
$5.25 M (USD), Series A
Dec 20, 2024
-
Investors
Mayo Clinic
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SimBioSys
SimBioSys offers a comprehensive portfolio of products and services, including TumorSight Viz, TumorSight RISK, and PhenoScope.
Transforms MRIs into 3D models for cancer preoperative planning.
Estimates cancer recurrence risk using patient data.
Analyzes biomarkers for therapy and dose optimization.
People of SimBioSys
Unlock access to complete
Unlock access to complete
Funding Insights of SimBioSys
SimBioSys has successfully raised a total of $20.25M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $5.25 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in SimBioSys
SimBioSys has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Mayo Clinic, Genoa Ventures and AV8 Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage VC firm focused on life science startups
|
Locked | Locked | Locked | |
|
Early-stage startups are supported by AV8 Ventures through investments.
|
Locked | Locked | Locked | |
|
Multi-stage tech and life sciences focused venture capital firm investing primarily in the US
|
Locked | Locked | Locked |
Investor details for SimBioSys
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SimBioSys
Investment portfolio details for SimBioSys
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - SimBioSys
Detailed financials for SimBioSys
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Simbiosys Comparisons
Peer comparison for SimBioSys
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SimBioSys
SimBioSys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Qure.ai, Subtle Medical, Perspectum, Zebra Medical Vision and Invicro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-powered solutions for medical imaging diagnostics
|
|
| Locked | Locked | Locked |
AI-driven solutions for medical diagnostic imaging are developed.
|
|
| Locked | Locked | Locked |
Precision medicine software for liver disease diagnosis is offered.
|
|
| Locked | Locked | Locked |
Provider of AI and SaaS-based medical image based decision support tools
|
|
| Locked | Locked | Locked |
Provide contract research imaging services and software
|
|
| Locked | Locked | Locked |
SaaS analytics platform for Medical Image Analysis
|
Detailed competitors of SimBioSys
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Simbiosys
Complete news archive for SimBioSys
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SimBioSys
SimBioSys was founded in 2016 and raised its 1st funding round 5 years after it was founded.
SimBioSys is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Tushar Pandey is the current CEO of SimBioSys.
SimBioSys is a funded company, having raised a total of $20.25M across 2 funding rounds to date.
SimBioSys was founded in 2016 in Chicago, United States, within the healthcare sector. AI-based decision-making and cancer diagnosis tools are offered to professionals. TumorScope software is utilized, incorporating AI and supercomputing to model cancer behavior from patient MRI, PET, or radiology scans. Pre-treatment predictions for lung, prostate, and breast cancers are generated through these operations.
SimBioSys's top competitors include Perspectum, Qure.ai and Subtle Medical.
SimBioSys offers TumorSight Viz, TumorSight RISK, and PhenoScope.
SimBioSys has 5 investors. Key investors include Mayo Clinic, Genoa Ventures, AV8 Ventures, Heritage Group, and Northpond Ventures.